<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<?release-delay 0|0?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">OR</journal-id>
<journal-title-group>
<journal-title>Oncology Reports</journal-title>
</journal-title-group>
<issn pub-type="ppub">1021-335X</issn>
<issn pub-type="epub">1791-2431</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/or.2017.5805</article-id>
<article-id pub-id-type="publisher-id">or-38-03-1411</article-id>
<article-categories>
<subj-group>
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The biological functions and mechanism of miR-212 in prostate cancer proliferation, migration and invasion via targeting Engrailed-2</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Yi</given-names></name>
<xref rid="af1-or-38-03-1411" ref-type="aff"/></contrib>
<contrib contrib-type="author"><name><surname>Ji</surname><given-names>Zhigang</given-names></name>
<xref rid="af1-or-38-03-1411" ref-type="aff"/></contrib>
<contrib contrib-type="author"><name><surname>Yan</surname><given-names>Weigang</given-names></name>
<xref rid="af1-or-38-03-1411" ref-type="aff"/>
<xref rid="c1-or-38-03-1411" ref-type="corresp"/></contrib>
<contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Zhien</given-names></name>
<xref rid="af1-or-38-03-1411" ref-type="aff"/></contrib>
<contrib contrib-type="author"><name><surname>Li</surname><given-names>Hanzhong</given-names></name>
<xref rid="af1-or-38-03-1411" ref-type="aff"/></contrib>
</contrib-group>
<aff id="af1-or-38-03-1411">Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100000, P.R. China</aff>
<author-notes>
<corresp id="c1-or-38-03-1411"><italic>Correspondence to</italic>: Dr Weigang Yan, Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, 1 ShuaiFu Garden, Dongcheng, Beijing 100000, P.R. China, E-mail: <email>bjyanweig@163.com</email></corresp>
</author-notes>
<pub-date pub-type="ppub"><month>03</month><year>2017</year></pub-date>
<pub-date pub-type="epub"><day>12</day><month>07</month><year>2017</year></pub-date>
<volume>38</volume>
<issue>3</issue>
<fpage>1411</fpage>
<lpage>1419</lpage>
<history>
<date date-type="received"><day>09</day><month>02</month><year>2017</year></date>
<date date-type="accepted"><day>06</day><month>07</month><year>2017</year></date>
</history>
<permissions>
<copyright-statement>Copyright: &#x00A9; Zhou et al.</copyright-statement>
<copyright-year>2017</copyright-year>
<license license-type="open-access">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivs License</ext-link>, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.</license-p></license>
</permissions>
<abstract>
<p>Accumulating evidence indicates that Engrailed-2 (EN-2), which is a homeobox-containing transcription factor, act as a candidate oncogene in prostate cancer (PCa). Even though there are some treatments targeting EN-2, however, it is limited because the mechanism of EN-2 upregulation in PCa cells is still unknown. In this study, we investigate the role of miR-212 on EN-2 expression and explored the mechanism of prostate cancer survival and metastasis. The relative expression levels of miR-212 and EN-2 in PCa samples and adjacent normal tissues as well as in PCa cell lines were detected by using quantitative real-time PCR. CCK-8, TUNEL and Transwell assays were used to analyze cell proliferation, apoptosis and invasion, respectively. EN-2 was identified as a direct target of miR-212 via luciferase reporter and western blot assays. Results showed that the expression level of miR-212 was downregulated in both PCa samples and PCa cell lines when compared with prostate epithelial cells and the adjacent no tumor tissues. Moreover, we found that overexpression of miR-212 suppressed PCa cell proliferation and invasion, promoted PCa cell apoptosis. EN-2 was identified as a direct target gene of miR-212 by using luciferase reporter and western blot assays. Also, the expression of EN-2 and miR-212 in the PCa cells had an opposite correlation. The critical role of miR-212 in inhibiting prostate tumor growth was verified in xenograft models of prostate cancer. These findings highlighted the role of miR-212 in PCa progression. More importantly, we speculate that EN-2 is a direct target gene of miR-212.</p>
</abstract>
<kwd-group>
<kwd>miR-212</kwd>
<kwd>prostate cancer</kwd>
<kwd>proliferation</kwd>
<kwd>migration</kwd>
<kwd>invasion</kwd>
<kwd>Engrailed-2</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Prostate cancer (PCa) is the second most commonly diagnosed malignancy all over the world, and one of the most common leading cause of cancer-specific mortality in men, which causes 913,000 new cases and &#x003E;261,000 deaths worldwide each year (<xref rid="b1-or-38-03-1411" ref-type="bibr">1</xref>,<xref rid="b2-or-38-03-1411" ref-type="bibr">2</xref>). As the development of prostate-specific antigen (PSA) serum level screening and the prostate biopsy through transrectal ultrasound-guided method, the detection rate and incidence of PCa is markedly increased (<xref rid="b3-or-38-03-1411" ref-type="bibr">3</xref>). Currently, therapeutic schedules for this disease in a localized stage or when it is still castration-sensitive would have good results in most of the patients. However, such handlings are only palliative in the advanced stage (<xref rid="b4-or-38-03-1411" ref-type="bibr">4</xref>). Therefore, new biomarkers and therapeutic targets should be found to get effective treatments for more aggressive stages in prostate cancer.</p>
<p>miRNAs are a kind of small, 20&#x2013;22 nucleotides non-coding RNAs that regulate the expression of hundreds of target genes through binding to the 3&#x2032;-untranslated region (3&#x2032;-UTR) of their target mRNAs (<xref rid="b5-or-38-03-1411" ref-type="bibr">5</xref>). miRNAs play critical roles in many kinds of physiological and pathological processes, such as apoptosis, cell proliferation, differentiation, development, stress response and migration (<xref rid="b6-or-38-03-1411" ref-type="bibr">6</xref>,<xref rid="b7-or-38-03-1411" ref-type="bibr">7</xref>). A growing number of evidence has revealed that miRNAs act as either tumor suppressors or promoters in the process of many kinds of tumors and play important roles in regulating the posttranscriptional gene expression (<xref rid="b8-or-38-03-1411" ref-type="bibr">8</xref>&#x2013;<xref rid="b10-or-38-03-1411" ref-type="bibr">10</xref>). miR-212 which is located on chromosome 17p13.3 and share an identical 5&#x2032;-seed sequence (<xref rid="b11-or-38-03-1411" ref-type="bibr">11</xref>). It has been demonstrated that miR-212 is markedly overexpressed in tongue squamous cell carcinoma (<xref rid="b12-or-38-03-1411" ref-type="bibr">12</xref>) and colorectal carcinoma (<xref rid="b13-or-38-03-1411" ref-type="bibr">13</xref>), but low-expressed in gastric cancer (<xref rid="b14-or-38-03-1411" ref-type="bibr">14</xref>) and non-small cell lung cancers (<xref rid="b15-or-38-03-1411" ref-type="bibr">15</xref>). Moreover, studies have shown that dysregulated miR-212 plays a critical role in the proliferation and invasion of many solid malignancies, which makes it a potential target for tumor treatment (<xref rid="b16-or-38-03-1411" ref-type="bibr">16</xref>). However, the exact function of miR-212 in PCa has not yet been studied.</p>
<p>Engrailed-2 (EN-2), which is a homeodomain-containing transcription factor, was recently verified to be involved in the development of prostate cancer (<xref rid="b17-or-38-03-1411" ref-type="bibr">17</xref>) and is also confirmed to express abnormally in prostate cancer cell lines (<xref rid="b18-or-38-03-1411" ref-type="bibr">18</xref>). Recent studies had shown that EN-2 is a potential biomarker for prostate cancer (<xref rid="b19-or-38-03-1411" ref-type="bibr">19</xref>,<xref rid="b20-or-38-03-1411" ref-type="bibr">20</xref>). While the regulatory mechanism and the role in progress of prostate cancer still almost known.</p>
<p>In this study, we aimed to detect the expression of miR-212 in PCa tissues and cell lines as well as to illustrate the role of miR-212 in PCa cell line proliferation, colony formation and migration. Importantly, we also illustrate EN-2 as a potential target gene of miR-212.</p>
</sec>
<sec sec-type="materials|methods">
<title>Materials and methods</title>
<sec>
<title/>
<sec>
<title>Collection and cell lines</title>
<p>Prostate cancer samples and the adjacent normal tissues were collected from 58 patients who underwent tumor-resection surgery in Peking Union Medical College Hospital from September 1, 2014 to January 1, 2016. Patients signed an informed consent form. The tissues were separately frozen in liquid nitrogen for further study. Protocols were approved by the institutional ethics committee of Peking Union Medical College Hospital and carried out in accordance with the guidelines for ethical management. PCa cell lines, PC3 and DU145, and prostate epithelial cells were purchased from American Type Culture Collection (ATCC, USA). PC3 was incubated in F-12 medium, and DU145 was grown in DMEM medium (Life Technologies, Inc., USA), and all the mediums were supplemented with penicillin/streptomycin (100 U/ml and 100 mg/ml, respectively) and 10&#x0025; fetal bovine serum (Life Technologies Inc.). The human prostate epithelial cells (hPrEC) were cultured in prostate epithelium basal media. All the cells were incubated at 37&#x00B0;C in a humidified atmosphere of 5&#x0025; CO<sub>2</sub>.</p>
</sec>
<sec>
<title>Quantitative real-time PCR</title>
<p>Total RNA was extracted from the tissues or cells via TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer&#x0027;s instructions and quantified with UV absorbancy at 260 and 280 nm (A260/280). Subsequently the RNA was reverse-transcribed into cDNA by using reverse transcription system (Thermo Scientific, CA, USA). The expression level of miR-212 was detected by the Applied Biosystems 7500 Real-time PCR system (ABI) using the TaqMan MicroRNA assay kits (Applied Biosystems, CA, USA). U6 was used as the control normalizer. The gene expression of EN-2 was also analyzed by SYBR Green and normalized with GAPDH. The specificity of primer sequences was analyzed by dissociation curve, 2<sup>&#x2212;&#x0394;&#x0394;Ct</sup> (cycle threshold) was used to calculate the relative gene expression levels.</p>
</sec>
<sec>
<title>Western blotting</title>
<p>Protein from tissues or cells was collected by using RIPA buffer which contain a protease inhibitor cocktail and phosphatase inhibitors (Sigma, St. Louis, MO, USA), according to the manufacturer&#x0027;s instructions and quantified via bicinchoninic acid (BCA) kit (Thermo Scientific). Protein samples (30 &#x00B5;g) were separated by SDS-PAGE and then transferred onto the polyvinylidene difluoride (PVDF, Millipore, Bedford, MA, USA) membranes. Western blotting was performed using anti-&#x03B2;-actin, anti-EN-2, anti-Bcl-2 and anti-Bax (CST, Denver, CO, USA). The protein levels were detected with an ECL kit (Thermo Scientific) according to the manufacturer&#x0027;s instructions.</p>
</sec>
<sec>
<title>CCK-8 assay measurements of the proliferation of PCa cells</title>
<p>CCK-8 assay was performed to evaluate cell proliferation according to the manufacturer&#x0027;s instructions. For experiments the cells were seeded at a density of 5&#x00D7;10<sup>3</sup> cells per well in 96-well plates and cultured for various periods of time (0, 24, 48 and 72 h). The absorbance at 450 nm was measured using an electroluminescence immunosorbent assay reader (Thermo Fisher Scientific, Waltham, MA, USA).</p>
</sec>
<sec>
<title>Apoptosis of PCa cells were detected by flow cytometry</title>
<p>Cells were collected and washed twice with cold phosphate-buffered saline solution (PBS) to remove floating cells then labeled with Annexin V-FITC (BD Biosciences, San Jose, CA, USA). Apoptosis were evaluated with a flow cytometry analyzer. Data were analyzed by Flowjo 7.6 software.</p>
</sec>
<sec>
<title>TUNEL detection of apoptosis of PCa cells</title>
<p>Cells were fixed with 4&#x0025; paraformaldehyde, permeabilized in 0.2&#x0025; Triton X-100, and incubated with the TUNEL detection kit from Roche (Roche, Shanghai, China) at 37&#x00B0;C for 1 h. The samples were mounted in mounting media containing DAPI. Fluorescent images were captured using a fluorescence microscope. The total number of DAPI positive cells and total number of TUNEL positive cells were counted.</p>
</sec>
<sec>
<title>Cell invasion assays</title>
<p>Cell invasion assays were performed by using 24-well Transwell plates (BD Biocoat, USA). Cells transfected with the miR-212 mimics and mimic control for 24 h. Then the cells were plated onto the 24-well upper chamber with a membrane that was pre-treated with Matrigel (100 &#x00B5;g per well; BD Biosciences). In the lower portion of the chamber, fresh medium containing 10&#x0025; FBS was added. After the cells were incubated for 24 h at 37&#x00B0;C, the cells in the upper chamber were removed. Invaded cells were fixed with 4&#x0025; formaldehyde, stained with 0.5&#x0025; crystal violet, and counted under a microscope.</p>
</sec>
<sec>
<title>Wound healing assay</title>
<p>Cells were seeded into 6-well plates. Wounds were created in the confluent cell monolayer using a 200-&#x00B5;l sterile pipette tip, and the other free-floating cells and debris were removed by washing with PBS three times. Medium was then added, and the culture plates were incubated at 37&#x00B0;C for another 24 or 48 h. Wound healing within the scraped wound line was measured at a 48-h time-point by using microscope (Nikon, Tokyo, Japan).</p>
</sec>
<sec>
<title>Dual luciferase reporter assay</title>
<p>TargetScan software (<uri xlink:href="http://www.targetscan.org/">http://www.targetscan.org/</uri>) was used to identify the potential target gene of miR-212. The putative miR-212 binding sites or mutant at the 3&#x2032;-UTR of EN-2 were cloned into a vector and EN-2 3&#x2032;-UTR WT or EN-2 3&#x2032;-UTR Mut, was generated, respectively. EN-2 3&#x2032;-UTR WT or EN-2 3&#x2032;-UTR Mut was transfected into PCa cells which stably overexpressed miR-212 and transfected with negative control. Dual-Luciferase Reporter assay system (Promega, Madison, WI, USA) was used to detect the luciferase activity 36 h after transfection.</p>
</sec>
<sec>
<title>Lentivirus production and transfection</title>
<p>The LV-miR-212 mimics and mimics control were purchased from Gene-Chem (Shanghai, China). Cells were seed into 24-well plates at a density of 30&#x0025; and cultured overnight before transfection. Cells were transfected with miR-212 mimics or mimics control by using Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer&#x0027;s protocols.</p>
</sec>
<sec>
<title>Animals and xenograft</title>
<p>In this study all the animal procedures and experiments were performed in accordance with the National Institutes of Health Guide for Care and Use of Laboratory Animals. The 6&#x2013;8-week-old nude male mice [BALB/c A-nu (nu/nu)] were purchased from Shanghai SLAC Laboratory Animal Co., Ltd. (Shanghai, China) and housed in the Animal Resource Facility at Laboratory Animal Centre. Cells stably expressing either miR-212 overexpression (LV-miR-212) or miRNA control were injected subcutaneously into the mice. The volume of the tumor was recorded for 7 weeks (once each week).</p>
</sec>
<sec>
<title>Statistical analysis</title>
<p>All quantitative data presented are the mean &#x00B1; SD from at least three independent experiments. The relationship between the expression level of miR-212 and clinicopathological parameters was examined using Fisher&#x0027;s exact test or &#x03C7;<sup>2</sup> test. One-way ANOVA test or Student&#x0027;s t-test was used to analyze the other date. The significant statistical differences level was set at P&#x003C;0.05. SPSS 18.0 and Graph Pad Prism 6.0 software were used for date analysis.</p>
</sec>
</sec>
</sec>
<sec sec-type="results">
<title>Results</title>
<sec>
<title/>
<sec>
<title>The expression level of miR-212 and EN-2 in human PCa tissues and PCa cell lines</title>
<p>In order to confirm the molecular mechanisms underlying PCa, we analyzed the expression level of miR-212 and EN-2 in a series of clinical PCa tissues. Results showed that miR-212 was markedly decreased in cancer samples when compared with the adjacent normal tissues (<xref rid="f1-or-38-03-1411" ref-type="fig">Fig. 1A</xref>). In contrary, the level of EN-2 mRNA was over-expressed (<xref rid="f1-or-38-03-1411" ref-type="fig">Fig. 1B</xref>). Subsequently, we measured the miR-212 and EN-2 level in PCa cell lines and the human prostate epithelial cells (hPrEC) by RT-qPCR. As shown in <xref rid="f1-or-38-03-1411" ref-type="fig">Fig. 1C</xref>, the expression level of miR-212 in PCa cells was significantly lower than that in hPrEC cells. While the expression level of EN-2 had the opposite trend (<xref rid="f1-or-38-03-1411" ref-type="fig">Fig. 1D</xref>). The relationship between miR-212 expression level and clinicopathological features in our PCa cases is presented in <xref rid="tI-or-38-03-1411" ref-type="table">Table I</xref>. The decreased miR-212 was significantly associated with high Gleason scores (P&#x003C;0.05). As shown in <xref rid="tI-or-38-03-1411" ref-type="table">Table I</xref>, the decreased levels of miR-212 was present in 3 of 11 (27.3&#x0025;) cases with low Gleason score (&#x003C;7), 8 of 17 (47.1&#x0025;) cases with Gleason score 7, but 21 of 30 (70.0&#x0025;) cases with high Gleason score (&#x003E;7). The expression level of miR-212 was obviously decreased in PCa patients with distant metastasis (P&#x003C;0.05). There were no statistically significant difference between miR-212 level and the age of the patients, PSA levels or tumor stage.</p>
</sec>
<sec>
<title>Upregulation of miR-212 inhibits PCa cell survival, proliferation, invasion and migration</title>
<p>Next, in order to verify the role of miR-212 in control PCa cell survival and progress, miR-212 mimics and miR-NC were transfected into DU145 cells, then cells were collected for analysis. The level of miR-212 was detected by qRT-PCR. Results showed that the expression level of miR-212 in the mimic group was markedly increased when compared with the control (<xref rid="f2-or-38-03-1411" ref-type="fig">Fig. 2</xref>). CCK-8 assay demonstrated that miR-212 upregulation significantly suppressed DU145 cells proliferation (<xref rid="f3-or-38-03-1411" ref-type="fig">Fig. 3A</xref>). Moreover, the TUNEL and flow cytometry assays demonstrated that the apoptosis of DU145 cells was increased when transfected with miR-212 mimics (<xref rid="f3-or-38-03-1411" ref-type="fig">Figs. 3B and C</xref> and <xref rid="f4-or-38-03-1411" ref-type="fig">4A</xref>), whereas, the protein expression levels of Bcl-2 decreased and Bax markedly increased in DU145 cells after transfected with miR-212 mimics (<xref rid="f4-or-38-03-1411" ref-type="fig">Fig. 4B</xref>). Subsequently, we measured the effect of miR-212 on cell invasion, the Transwell assays indicated that miR-212 mimics transfected DU145 cells markedly suppressed cell invasion ability when compared to the mimic control cells (<xref rid="f3-or-38-03-1411" ref-type="fig">Fig. 3D and E</xref>). A similar tendency was discovered in the wound healing assays (<xref rid="f5-or-38-03-1411" ref-type="fig">Fig. 5</xref>). These outcomes clearly suggested that restoration of the expression of miR-212 inhibits PCa cell proliferation, invasion and migration.</p>
</sec>
<sec>
<title>miR-212 decreases EN-2 expression by binding to 3&#x2032;-UTR of its mRNA</title>
<p>In order to illustrate that EN-2 is a direct target of miR-212, EN-2 wild-type (WT) or mutant 3&#x2032;-UTR (Mut) (<xref rid="f6-or-38-03-1411" ref-type="fig">Fig. 6A</xref>) were subcloned into a luciferase reporter vector and co-transfected with miR-212 mimics or negative control (NC) into PCa cells. Then, luciferase activity was detected after 48-h transfection. The results demonstrated that miR-212 markedly inhibited luciferase activity of the EN-2 WT 3&#x2032;-UTR but had no influence on the mutant (<xref rid="f6-or-38-03-1411" ref-type="fig">Fig. 6B</xref>). To verify whether miR-212 can regulate the expression of EN-2, miR-212 mimics was transfected into DU145 cells for analysis. Results showed that the mRNA and protein level of EN-2 was markedly suppressed by miR-212 upregulation (<xref rid="f6-or-38-03-1411" ref-type="fig">Figs. 6C-E</xref> and <xref rid="f8-or-38-03-1411" ref-type="fig">8</xref>).</p>
</sec>
<sec>
<title>EN-2 re-introduction reverses the anti-cell survival and metastasis role of miR-212</title>
<p>In order to study the effect of EN-2 in PCa survival and invasion, miR-212 mimics and pcDNA-EN-2 were co-transfected into PCa cell lines, and after transfected for 48 h, cell survival and the ability of invasion were measured. Results showed that restoration of EN-2 reversed the anti-cell survival actions of miR-212 and the cell proliferation ability also recovered in comparison to miR-212 mimics (<xref rid="f3-or-38-03-1411" ref-type="fig">Figs. 3A-C</xref> and <xref rid="f4-or-38-03-1411" ref-type="fig">4A</xref>). Moreover, the capability of invasion of PCa cells was significantly restored via upregulation of EN-2 when compared with miR-212 mimics (<xref rid="f3-or-38-03-1411" ref-type="fig">Fig. 3D and E</xref>), the migration ability of PCa cells was markedly increased by EN-2 restoration when compared with miR-212 mimics (<xref rid="f5-or-38-03-1411" ref-type="fig">Fig. 5</xref>).</p>
</sec>
<sec>
<title>Upregulation of miR-212 suppresses PCa growth in vivo</title>
<p>In order to confirm the role of miR-212 against tumor growth <italic>in vivo</italic>, an animal model was made by nude mice subcutaneously injected with LV-miR-212. The tumor volume of subcutaneous xenograft tumors in nude mice apparently decreased with miR-212 upregulation when compared with the LV-control and the significant difference emerged from 4-week post-tumor transplantation (<xref rid="f7-or-38-03-1411" ref-type="fig">Fig. 7</xref>).</p>
</sec>
</sec>
</sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>PCa is the most frequently diagnosed malignance in men, and it is the second cause of tumor-related death in developed countries (<xref rid="b1-or-38-03-1411" ref-type="bibr">1</xref>,<xref rid="b21-or-38-03-1411" ref-type="bibr">21</xref>). Therefore, the early diagnosis is of great importance to allow successful treatment. Currently, the main methods for PCa diagnosis are PSA testing, digital rectal examination (DRE), PCA3, multiparametric magnetic resonance image (mpMRI) and Gleason score (<xref rid="b22-or-38-03-1411" ref-type="bibr">22</xref>). However, the therapeutic approaches are relatively limited. miRNAs are a series of small non-coding RNAs that are widely involved in both physiological and pathological condition (<xref rid="b23-or-38-03-1411" ref-type="bibr">23</xref>&#x2013;<xref rid="b25-or-38-03-1411" ref-type="bibr">25</xref>). For example, miR-135a and miR-21 are separately taken part in the cancer pathological process and insulin resistance (<xref rid="b26-or-38-03-1411" ref-type="bibr">26</xref>,<xref rid="b27-or-38-03-1411" ref-type="bibr">27</xref>). At the same time, there are studies also reporting that miR-125b and miR-449a are respectively, participating in the physiological condition of apoptosis and autophagy (<xref rid="b28-or-38-03-1411" ref-type="bibr">28</xref>,<xref rid="b29-or-38-03-1411" ref-type="bibr">29</xref>). It has been widely spread that dysregulation of miRNAs may cause cells dysfunction and further give rise to oncogenesis (<xref rid="b30-or-38-03-1411" ref-type="bibr">30</xref>). Therefore, research on miRNAs may illustrate the understanding of PCa development and be a great help for recognizing potential biomarkers.</p>
<p>miR-212 is one of the most important miRNAs that has been studied in many kinds of cancers, including hepatocellular carcinoma and pancreatic cancer (<xref rid="b31-or-38-03-1411" ref-type="bibr">31</xref>,<xref rid="b32-or-38-03-1411" ref-type="bibr">32</xref>). In our study, we firstly investigated the expression level of miR-212 in PCa patients and found that it was markedly decreased in PCa patient tissues than in the adjacent normal tissues. In PCa cell lines, the level of miR-212 also decreased compared to the hPrEC. Importantly, the low level of miR-212 has a significant correlation with high Gleason score and distant metastasis. These results suggested that miR-212 play an important role in the pathogenesis of PCa.</p>
<p>Previous research has revealed that miR-212 negatively regulates starvation-induced autophagy in PCa cells by inhibiting SIRT1, upregulation of miR-212 also leads to suppression of angiogenesis and cellular senescence (<xref rid="b33-or-38-03-1411" ref-type="bibr">33</xref>). In this study, overexpression of miR-212 significantly suppressed cell proliferation, invasion and migration, and markedly promoted apoptosis of PCa cells. Bcl-2 and Bax are apoptosis-related genes. In this study, we found that upregulation of miR-212, regulates Bcl-2 family members, the level of Bax increased and the Bcl-2 decreased, while the recovery of EN-2 promoted the Bcl-2 resistance to apoptosis and inhibited Bax promoting apoptosis. Which was consistent with the above previous study. In order to further research the function of miR-212 in PCa cells, we detected the role of miR-212 in the growth of subcutaneous xenograft tumors in nude mice. In accordance with the <italic>in vitro</italic> study, upregulation of the expression of miR-212 suppressed the growth of xenograft tumors <italic>in vivo</italic>. Collectively, these results sustained the concept that miR-212 may act as a tumor suppressor in PCa.</p>
<p>Many target genes for miR-212 have been found in various kinds of malignancies such as Lin28B in PCa (<xref rid="b34-or-38-03-1411" ref-type="bibr">34</xref>). There are also some other targets for miR-212, including RB, SMAD2, FOXA1 and SGK3 have been reported in some other cancers (<xref rid="b11-or-38-03-1411" ref-type="bibr">11</xref>,<xref rid="b32-or-38-03-1411" ref-type="bibr">32</xref>,<xref rid="b35-or-38-03-1411" ref-type="bibr">35</xref>,<xref rid="b36-or-38-03-1411" ref-type="bibr">36</xref>). Although the role of miR-212 has been studied in many tumors, its mechanistic role in PCa is still unclear. Increasing evidence has recognized that EN-2 acts as a novel well-known biomarker for diagnosing PCa (<xref rid="b37-or-38-03-1411" ref-type="bibr">37</xref>,<xref rid="b38-or-38-03-1411" ref-type="bibr">38</xref>), while its effect on PCa oncogenesis has not been defined. There are also studies demonstrating that the expression of EN-2 dysregulated in many human cancers, and inhibiting EN-2 expression can suppress the development of bladder cancer and chronic myelogenous leukemia (<xref rid="b39-or-38-03-1411" ref-type="bibr">39</xref>,<xref rid="b40-or-38-03-1411" ref-type="bibr">40</xref>), which suggested that EN-2 play an important role in the progression of cancer. In order to study the involvement of EN-2 and the role of interaction between miR-212 and EN-2 in oncogenesis of PCa, we studied PCa cell activity in DU145 cells co-transfected with miR-212 mimics and pcDNA-EN-2. Results demonstrated that EN-2 restoration effectively reversed repressive effect of miR-212 on cell survival and progression. In this study, we also confirmed that EN-2 was as a direct target gene of miR-212 in PCa cells.</p>
<p>As demonstrated above, the level of miR-212 was downregulated in PCa patients and the cell lines. Upregulation of miR-212 markedly suppressed PCa cell proliferation and promoted apoptosis and it may be via targeting EN-2. Our findings introduced a better understanding of miR-212 in PCa progression, which is likely to provide more precise targets for diagnostic and therapeutics against PCa, and we will carry out further study to confirm this suggestion.</p>
</sec>
</body>
<back>
<glossary>
<def-list>
<title>Abbreviations</title>
<def-item><term>PCa</term><def><p>prostate cancer</p></def></def-item>
<def-item><term>EN-2</term><def><p>Engrailed-2</p></def></def-item>
<def-item><term>PSA</term><def><p>prostate specific antigen</p></def></def-item>
</def-list>
</glossary>
<ref-list>
<title>References</title>
<ref id="b1-or-38-03-1411"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Miller</surname><given-names>KD</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><article-title>Cancer statistics, 2015</article-title><source>CA Cancer J Clin</source><volume>65</volume><fpage>5</fpage><lpage>29</lpage><year>2015</year><pub-id pub-id-type="doi">10.3322/caac.21254</pub-id><pub-id pub-id-type="pmid">25559415</pub-id></element-citation></ref>
<ref id="b2-or-38-03-1411"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Shin</surname><given-names>HR</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Forman</surname><given-names>D</given-names></name><name><surname>Mathers</surname><given-names>C</given-names></name><name><surname>Parkin</surname><given-names>DM</given-names></name></person-group><article-title>Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008</article-title><source>Int J Cancer</source><volume>127</volume><fpage>2893</fpage><lpage>2917</lpage><year>2010</year><pub-id pub-id-type="doi">10.1002/ijc.25516</pub-id><pub-id pub-id-type="pmid">21351269</pub-id></element-citation></ref>
<ref id="b3-or-38-03-1411"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuzick</surname><given-names>J</given-names></name><name><surname>Thorat</surname><given-names>MA</given-names></name><name><surname>Andriole</surname><given-names>G</given-names></name><name><surname>Brawley</surname><given-names>OW</given-names></name><name><surname>Brown</surname><given-names>PH</given-names></name><name><surname>Culig</surname><given-names>Z</given-names></name><name><surname>Eeles</surname><given-names>RA</given-names></name><name><surname>Ford</surname><given-names>LG</given-names></name><name><surname>Hamdy</surname><given-names>FC</given-names></name><name><surname>Holmberg</surname><given-names>L</given-names></name><etal/></person-group><article-title>Prevention and early detection of prostate cancer</article-title><source>Lancet Oncol</source><volume>15</volume><fpage>e484</fpage><lpage>e492</lpage><year>2014</year><pub-id pub-id-type="doi">10.1016/S1470-2045(14)70211-6</pub-id><pub-id pub-id-type="pmid">25281467</pub-id><pub-id pub-id-type="pmcid">4203149</pub-id></element-citation></ref>
<ref id="b4-or-38-03-1411"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>FZ</given-names></name><name><surname>Zhao</surname><given-names>XK</given-names></name></person-group><article-title>Prostate cancer: Current treatment and prevention strategies</article-title><source>Iran Red Crescent Med J</source><volume>15</volume><fpage>279</fpage><lpage>284</lpage><year>2013</year><pub-id pub-id-type="doi">10.5812/ircmj.6499</pub-id><pub-id pub-id-type="pmid">24082997</pub-id><pub-id pub-id-type="pmcid">3785898</pub-id></element-citation></ref>
<ref id="b5-or-38-03-1411"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartel</surname><given-names>DP</given-names></name></person-group><article-title>MicroRNAs: Target recognition and regulatory functions</article-title><source>Cell</source><volume>136</volume><fpage>215</fpage><lpage>233</lpage><year>2009</year><pub-id pub-id-type="doi">10.1016/j.cell.2009.01.002</pub-id><pub-id pub-id-type="pmid">19167326</pub-id><pub-id pub-id-type="pmcid">3794896</pub-id></element-citation></ref>
<ref id="b6-or-38-03-1411"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steinfeld</surname><given-names>I</given-names></name><name><surname>Navon</surname><given-names>R</given-names></name><name><surname>Ach</surname><given-names>R</given-names></name><name><surname>Yakhini</surname><given-names>Z</given-names></name></person-group><article-title>miRNA target enrichment analysis reveals directly active miRNAs in health and disease</article-title><source>Nucleic Acids Res</source><volume>41</volume><fpage>e45</fpage><year>2013</year><pub-id pub-id-type="doi">10.1093/nar/gks1142</pub-id><pub-id pub-id-type="pmid">23209027</pub-id></element-citation></ref>
<ref id="b7-or-38-03-1411"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Medina</surname><given-names>PP</given-names></name><name><surname>Slack</surname><given-names>FJ</given-names></name></person-group><article-title>microRNAs and cancer: An overview</article-title><source>Cell Cycle</source><volume>7</volume><fpage>2485</fpage><lpage>2492</lpage><year>2008</year><pub-id pub-id-type="doi">10.4161/cc.7.16.6453</pub-id><pub-id pub-id-type="pmid">18719380</pub-id></element-citation></ref>
<ref id="b8-or-38-03-1411"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Kouwenhove</surname><given-names>M</given-names></name><name><surname>Kedde</surname><given-names>M</given-names></name><name><surname>Agami</surname><given-names>R</given-names></name></person-group><article-title>MicroRNA regulation by RNA-binding proteins and its implications for cancer</article-title><source>Nat Rev Cancer</source><volume>11</volume><fpage>644</fpage><lpage>656</lpage><year>2011</year><pub-id pub-id-type="doi">10.1038/nrc3107</pub-id><pub-id pub-id-type="pmid">21822212</pub-id></element-citation></ref>
<ref id="b9-or-38-03-1411"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calin</surname><given-names>GA</given-names></name><name><surname>Croce</surname><given-names>CM</given-names></name></person-group><article-title>MicroRNA signatures in human cancers</article-title><source>Nat Rev Cancer</source><volume>6</volume><fpage>857</fpage><lpage>866</lpage><year>2006</year><pub-id pub-id-type="doi">10.1038/nrc1997</pub-id><pub-id pub-id-type="pmid">17060945</pub-id></element-citation></ref>
<ref id="b10-or-38-03-1411"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dalmay</surname><given-names>T</given-names></name></person-group><article-title>Mechanism of miRNA-mediated repression of mRNA translation</article-title><source>Essays Biochem</source><volume>54</volume><fpage>29</fpage><lpage>38</lpage><year>2013</year><pub-id pub-id-type="doi">10.1042/bse0540029</pub-id><pub-id pub-id-type="pmid">23829525</pub-id></element-citation></ref>
<ref id="b11-or-38-03-1411"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>JK</given-names></name><name><surname>Henry</surname><given-names>JC</given-names></name><name><surname>Jiang</surname><given-names>J</given-names></name><name><surname>Esau</surname><given-names>C</given-names></name><name><surname>Gusev</surname><given-names>Y</given-names></name><name><surname>Lerner</surname><given-names>MR</given-names></name><name><surname>Postier</surname><given-names>RG</given-names></name><name><surname>Brackett</surname><given-names>DJ</given-names></name><name><surname>Schmittgen</surname><given-names>TD</given-names></name></person-group><article-title>miR-132 and miR-212 are increased in pancreatic cancer and target the retinoblastoma tumor suppressor</article-title><source>Biochem Biophys Res Commun</source><volume>406</volume><fpage>518</fpage><lpage>523</lpage><year>2011</year><pub-id pub-id-type="doi">10.1016/j.bbrc.2011.02.065</pub-id><pub-id pub-id-type="pmid">21329664</pub-id><pub-id pub-id-type="pmcid">3069485</pub-id></element-citation></ref>
<ref id="b12-or-38-03-1411"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scapoli</surname><given-names>L</given-names></name><name><surname>Palmieri</surname><given-names>A</given-names></name><name><surname>Lo Muzio</surname><given-names>L</given-names></name><name><surname>Pezzetti</surname><given-names>F</given-names></name><name><surname>Rubini</surname><given-names>C</given-names></name><name><surname>Girardi</surname><given-names>A</given-names></name><name><surname>Farinella</surname><given-names>F</given-names></name><name><surname>Mazzotta</surname><given-names>M</given-names></name><name><surname>Carinci</surname><given-names>F</given-names></name></person-group><article-title>MicroRNA expression profiling of oral carcinoma identifies new markers of tumor progression</article-title><source>Int J Immunopathol Pharmacol</source><volume>23</volume><fpage>1229</fpage><lpage>1234</lpage><year>2010</year><pub-id pub-id-type="doi">10.1177/039463201002300427</pub-id><pub-id pub-id-type="pmid">21244772</pub-id></element-citation></ref>
<ref id="b13-or-38-03-1411"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schetter</surname><given-names>AJ</given-names></name><name><surname>Leung</surname><given-names>SY</given-names></name><name><surname>Sohn</surname><given-names>JJ</given-names></name><name><surname>Zanetti</surname><given-names>KA</given-names></name><name><surname>Bowman</surname><given-names>ED</given-names></name><name><surname>Yanaihara</surname><given-names>N</given-names></name><name><surname>Yuen</surname><given-names>ST</given-names></name><name><surname>Chan</surname><given-names>TL</given-names></name><name><surname>Kwong</surname><given-names>DL</given-names></name><name><surname>Au</surname><given-names>GK</given-names></name><etal/></person-group><article-title>MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma</article-title><source>JAMA</source><volume>299</volume><fpage>425</fpage><lpage>436</lpage><year>2008</year><pub-id pub-id-type="doi">10.1001/jama.299.4.425</pub-id><pub-id pub-id-type="pmid">18230780</pub-id><pub-id pub-id-type="pmcid">2614237</pub-id></element-citation></ref>
<ref id="b14-or-38-03-1411"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wada</surname><given-names>R</given-names></name><name><surname>Akiyama</surname><given-names>Y</given-names></name><name><surname>Hashimoto</surname><given-names>Y</given-names></name><name><surname>Fukamachi</surname><given-names>H</given-names></name><name><surname>Yuasa</surname><given-names>Y</given-names></name></person-group><article-title>miR-212 is downregulated and suppresses methyl-CpG-binding protein MeCP2 in human gastric cancer</article-title><source>Int J Cancer</source><volume>127</volume><fpage>1106</fpage><lpage>1114</lpage><year>2010</year><pub-id pub-id-type="doi">10.1002/ijc.25126</pub-id><pub-id pub-id-type="pmid">20020497</pub-id></element-citation></ref>
<ref id="b15-or-38-03-1411"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Incoronato</surname><given-names>M</given-names></name><name><surname>Garofalo</surname><given-names>M</given-names></name><name><surname>Urso</surname><given-names>L</given-names></name><name><surname>Romano</surname><given-names>G</given-names></name><name><surname>Quintavalle</surname><given-names>C</given-names></name><name><surname>Zanca</surname><given-names>C</given-names></name><name><surname>Iaboni</surname><given-names>M</given-names></name><name><surname>Nuovo</surname><given-names>G</given-names></name><name><surname>Croce</surname><given-names>CM</given-names></name><name><surname>Condorelli</surname><given-names>G</given-names></name></person-group><article-title>miR-212 increases tumor necrosis factor-related apoptosis-inducing ligand sensitivity in non-small cell lung cancer by targeting the antiapoptotic protein PED</article-title><source>Cancer Res</source><volume>70</volume><fpage>3638</fpage><lpage>3646</lpage><year>2010</year><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-3341</pub-id><pub-id pub-id-type="pmid">20388802</pub-id></element-citation></ref>
<ref id="b16-or-38-03-1411"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehta</surname><given-names>A</given-names></name><name><surname>Mann</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>JL</given-names></name><name><surname>Marinov</surname><given-names>GK</given-names></name><name><surname>Majumdar</surname><given-names>D</given-names></name><name><surname>Garcia-Flores</surname><given-names>Y</given-names></name><name><surname>Du</surname><given-names>X</given-names></name><name><surname>Erikci</surname><given-names>E</given-names></name><name><surname>Chowdhury</surname><given-names>K</given-names></name><name><surname>Baltimore</surname><given-names>D</given-names></name></person-group><article-title>The microRNA-212/132 cluster regulates B cell development by targeting Sox4</article-title><source>J Exp Med</source><volume>212</volume><fpage>1679</fpage><lpage>1692</lpage><year>2015</year><pub-id pub-id-type="doi">10.1084/jem.20150489</pub-id><pub-id pub-id-type="pmid">26371188</pub-id><pub-id pub-id-type="pmcid">4577845</pub-id></element-citation></ref>
<ref id="b17-or-38-03-1411"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morgan</surname><given-names>R</given-names></name><name><surname>Boxall</surname><given-names>A</given-names></name><name><surname>Bhatt</surname><given-names>A</given-names></name><name><surname>Bailey</surname><given-names>M</given-names></name><name><surname>Hindley</surname><given-names>R</given-names></name><name><surname>Langley</surname><given-names>S</given-names></name><name><surname>Whitaker</surname><given-names>HC</given-names></name><name><surname>Neal</surname><given-names>DE</given-names></name><name><surname>Ismail</surname><given-names>M</given-names></name><name><surname>Whitaker</surname><given-names>H</given-names></name><etal/></person-group><article-title>Engrailed-2 (EN2): A tumor specific urinary biomarker for the early diagnosis of prostate cancer</article-title><source>Clin Cancer Res</source><volume>17</volume><fpage>1090</fpage><lpage>1098</lpage><year>2011</year><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-10-2410</pub-id><pub-id pub-id-type="pmid">21364037</pub-id></element-citation></ref>
<ref id="b18-or-38-03-1411"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bose</surname><given-names>SK</given-names></name><name><surname>Bullard</surname><given-names>RS</given-names></name><name><surname>Donald</surname><given-names>CD</given-names></name></person-group><article-title>Oncogenic role of engrailed-2 (en-2) in prostate cancer cell growth and survival</article-title><source>Transl Oncogenomics</source><volume>3</volume><fpage>37</fpage><lpage>43</lpage><year>2008</year><pub-id pub-id-type="pmid">21566742</pub-id><pub-id pub-id-type="pmcid">3022358</pub-id></element-citation></ref>
<ref id="b19-or-38-03-1411"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marsza&#x0142;&#x0142;</surname><given-names>MP</given-names></name><name><surname>Sroka</surname><given-names>W</given-names></name><name><surname>Adamowski</surname><given-names>M</given-names></name><name><surname>S&#x0142;upski</surname><given-names>P</given-names></name><name><surname>Jarzemski</surname><given-names>P</given-names></name><name><surname>Si&#x00F3;dmiak</surname><given-names>J</given-names></name><name><surname>Odrow&#x0105;&#x017C;-Sypniewska</surname><given-names>G</given-names></name></person-group><article-title>Engrailed-2 protein as a potential urinary prostate cancer biomarker: A comparison study before and after digital rectal examination</article-title><source>Eur J Cancer Prev</source><volume>24</volume><fpage>51</fpage><lpage>56</lpage><year>2015</year><pub-id pub-id-type="doi">10.1097/CEJ.0000000000000046</pub-id><pub-id pub-id-type="pmid">25003607</pub-id></element-citation></ref>
<ref id="b20-or-38-03-1411"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGrath</surname><given-names>SE</given-names></name><name><surname>Michael</surname><given-names>A</given-names></name><name><surname>Morgan</surname><given-names>R</given-names></name><name><surname>Pandha</surname><given-names>H</given-names></name></person-group><article-title>EN2: A novel prostate cancer biomarker</article-title><source>Biomarkers Med</source><volume>7</volume><fpage>893</fpage><lpage>901</lpage><year>2013</year><pub-id pub-id-type="doi">10.2217/bmm.13.115</pub-id></element-citation></ref>
<ref id="b21-or-38-03-1411"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Steliarova-Foucher</surname><given-names>E</given-names></name><name><surname>Lortet-Tieulent</surname><given-names>J</given-names></name><name><surname>Rosso</surname><given-names>S</given-names></name><name><surname>Coebergh</surname><given-names>JW</given-names></name><name><surname>Comber</surname><given-names>H</given-names></name><name><surname>Forman</surname><given-names>D</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name></person-group><article-title>Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012</article-title><source>Eur J Cancer</source><volume>49</volume><fpage>1374</fpage><lpage>1403</lpage><year>2013</year><pub-id pub-id-type="doi">10.1016/j.ejca.2012.12.027</pub-id><pub-id pub-id-type="pmid">23485231</pub-id></element-citation></ref>
<ref id="b22-or-38-03-1411"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertoli</surname><given-names>G</given-names></name><name><surname>Cava</surname><given-names>C</given-names></name><name><surname>Castiglioni</surname><given-names>I</given-names></name></person-group><article-title>MicroRNAs as biomarkers for diagnosis, prognosis and theranostics in prostate cancer</article-title><source>Int J Mol Sci</source><volume>17</volume><fpage>421</fpage><year>2016</year><pub-id pub-id-type="doi">10.3390/ijms17030421</pub-id><pub-id pub-id-type="pmid">27011184</pub-id><pub-id pub-id-type="pmcid">4813272</pub-id></element-citation></ref>
<ref id="b23-or-38-03-1411"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kloosterman</surname><given-names>WP</given-names></name><name><surname>Plasterk</surname><given-names>RH</given-names></name></person-group><article-title>The diverse functions of microRNAs in animal development and disease</article-title><source>Dev Cell</source><volume>11</volume><fpage>441</fpage><lpage>450</lpage><year>2006</year><pub-id pub-id-type="doi">10.1016/j.devcel.2006.09.009</pub-id><pub-id pub-id-type="pmid">17011485</pub-id></element-citation></ref>
<ref id="b24-or-38-03-1411"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ha</surname><given-names>TY</given-names></name></person-group><article-title>MicroRNAs in human diseases: From cancer to cardiovascular disease</article-title><source>Immune Netw</source><volume>11</volume><fpage>135</fpage><lpage>154</lpage><year>2011</year><pub-id pub-id-type="doi">10.4110/in.2011.11.3.135</pub-id><pub-id pub-id-type="pmid">21860607</pub-id><pub-id pub-id-type="pmcid">3153666</pub-id></element-citation></ref>
<ref id="b25-or-38-03-1411"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baranwal</surname><given-names>S</given-names></name><name><surname>Alahari</surname><given-names>SK</given-names></name></person-group><article-title>miRNA control of tumor cell invasion and metastasis</article-title><source>Int J Cancer</source><volume>126</volume><fpage>1283</fpage><lpage>1290</lpage><year>2010</year><pub-id pub-id-type="pmid">19877123</pub-id><pub-id pub-id-type="pmcid">2950784</pub-id></element-citation></ref>
<ref id="b26-or-38-03-1411"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Ji</surname><given-names>A</given-names></name><name><surname>Jiang</surname><given-names>L</given-names></name><name><surname>Sang</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>F</given-names></name></person-group><article-title>miR-135a acts as a tumor suppressor in gastric cancer in part by targeting KIFC1</article-title><source>Onco Targets Ther</source><volume>9</volume><fpage>3555</fpage><lpage>3563</lpage><year>2016</year><pub-id pub-id-type="pmid">27366092</pub-id><pub-id pub-id-type="pmcid">4913988</pub-id></element-citation></ref>
<ref id="b27-or-38-03-1411"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>XY</given-names></name><name><surname>Shao</surname><given-names>K</given-names></name></person-group><article-title>Roles of MicroRNA-21 in the pathogenesis of insulin resistance and diabetic mellitus-induced non-alcoholic fatty liver disease</article-title><source>Zhongguo Yi Xue Ke Xue Yuan Xue Bao</source><volume>38</volume><fpage>144</fpage><lpage>149</lpage><year>2016</year><comment>(In Chinese)</comment><pub-id pub-id-type="pmid">27181889</pub-id></element-citation></ref>
<ref id="b28-or-38-03-1411"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>G</given-names></name><name><surname>Zhan</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name></person-group><article-title>Overexpression of miR-125b promotes apoptosis of macrophages</article-title><source>Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi</source><volume>32</volume><fpage>958</fpage><lpage>962</lpage><year>2016</year><comment>(In Chinese)</comment><pub-id pub-id-type="pmid">27363278</pub-id></element-citation></ref>
<ref id="b29-or-38-03-1411"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>R</given-names></name><name><surname>Ji</surname><given-names>X</given-names></name><name><surname>Rong</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Yao</surname><given-names>W</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Yan</surname><given-names>W</given-names></name><name><surname>Han</surname><given-names>L</given-names></name><etal/></person-group><article-title>miR-449a regulates autophagy to inhibit silica-induced pulmonary fibrosis through targeting Bcl2</article-title><source>J Mol Med (Berl)</source><volume>94</volume><fpage>1267</fpage><lpage>1279</lpage><year>2016</year><pub-id pub-id-type="doi">10.1007/s00109-016-1441-0</pub-id><pub-id pub-id-type="pmid">27351886</pub-id></element-citation></ref>
<ref id="b30-or-38-03-1411"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouyssou</surname><given-names>JM</given-names></name><name><surname>Manier</surname><given-names>S</given-names></name><name><surname>Huynh</surname><given-names>D</given-names></name><name><surname>Issa</surname><given-names>S</given-names></name><name><surname>Roccaro</surname><given-names>AM</given-names></name><name><surname>Ghobrial</surname><given-names>IM</given-names></name></person-group><article-title>Regulation of microRNAs in cancer metastasis</article-title><source>Biochim Biophys Acta</source><volume>1845</volume><fpage>255</fpage><lpage>265</lpage><year>2014</year><pub-id pub-id-type="pmid">24569228</pub-id><pub-id pub-id-type="pmcid">4170185</pub-id></element-citation></ref>
<ref id="b31-or-38-03-1411"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>C</given-names></name><name><surname>Nong</surname><given-names>K</given-names></name><name><surname>Wu</surname><given-names>B</given-names></name><name><surname>Dong</surname><given-names>B</given-names></name><name><surname>Bai</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Yuan</surname><given-names>Z</given-names></name><name><surname>Ai</surname><given-names>K</given-names></name></person-group><article-title>miR-212 promotes pancreatic cancer cell growth and invasion by targeting the hedgehog signaling pathway receptor patched-1</article-title><source>J Exp Clin Cancer Res</source><volume>33</volume><fpage>54</fpage><year>2014</year><pub-id pub-id-type="doi">10.1186/1756-9966-33-54</pub-id><pub-id pub-id-type="pmid">24961235</pub-id><pub-id pub-id-type="pmcid">4085644</pub-id></element-citation></ref>
<ref id="b32-or-38-03-1411"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tu</surname><given-names>H</given-names></name><name><surname>Wei</surname><given-names>G</given-names></name><name><surname>Cai</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>Z</given-names></name><name><surname>Cheng</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>B</given-names></name><etal/></person-group><article-title>MicroRNA-212 inhibits hepatocellular carcinoma cell proliferation and induces apoptosis by targeting FOXA1</article-title><source>Onco Targets Ther</source><volume>8</volume><fpage>2227</fpage><lpage>2235</lpage><year>2015</year><pub-id pub-id-type="pmid">26347321</pub-id><pub-id pub-id-type="pmcid">4556035</pub-id></element-citation></ref>
<ref id="b33-or-38-03-1411"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramalinga</surname><given-names>M</given-names></name><name><surname>Roy</surname><given-names>A</given-names></name><name><surname>Srivastava</surname><given-names>A</given-names></name><name><surname>Bhattarai</surname><given-names>A</given-names></name><name><surname>Harish</surname><given-names>V</given-names></name><name><surname>Suy</surname><given-names>S</given-names></name><name><surname>Collins</surname><given-names>S</given-names></name><name><surname>Kumar</surname><given-names>D</given-names></name></person-group><article-title>MicroRNA-212 negatively regulates starvation induced autophagy in prostate cancer cells by inhibiting SIRT1 and is a modulator of angiogenesis and cellular senescence</article-title><source>Oncotarget</source><volume>6</volume><fpage>34446</fpage><lpage>34457</lpage><year>2015</year><pub-id pub-id-type="pmid">26439987</pub-id><pub-id pub-id-type="pmcid">4741465</pub-id></element-citation></ref>
<ref id="b34-or-38-03-1411"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borrego-Diaz</surname><given-names>E</given-names></name><name><surname>Powers</surname><given-names>BC</given-names></name><name><surname>Azizov</surname><given-names>V</given-names></name><name><surname>Lovell</surname><given-names>S</given-names></name><name><surname>Reyes</surname><given-names>R</given-names></name><name><surname>Chapman</surname><given-names>B</given-names></name><name><surname>Tawfik</surname><given-names>O</given-names></name><name><surname>McGregor</surname><given-names>D</given-names></name><name><surname>Diaz</surname><given-names>FJ</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><etal/></person-group><article-title>A potential regulatory loop between Lin28B:miR-212 in androgen-independent prostate cancer</article-title><source>Int J Oncol</source><volume>45</volume><fpage>2421</fpage><lpage>2429</lpage><year>2014</year><pub-id pub-id-type="pmid">25201220</pub-id><pub-id pub-id-type="pmcid">4215582</pub-id></element-citation></ref>
<ref id="b35-or-38-03-1411"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>JL</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>JH</given-names></name><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Tang</surname><given-names>H</given-names></name></person-group><article-title>miR-212/132 downregulates SMAD2 expression to suppress the G1/S phase transition of the cell cycle and the epithelial to mesenchymal transition in cervical cancer cells</article-title><source>IUBMB Life</source><volume>67</volume><fpage>380</fpage><lpage>394</lpage><year>2015</year><pub-id pub-id-type="doi">10.1002/iub.1381</pub-id><pub-id pub-id-type="pmid">25988335</pub-id></element-citation></ref>
<ref id="b36-or-38-03-1411"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Shen</surname><given-names>C</given-names></name><name><surname>Yin</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Hou</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><etal/></person-group><article-title>miR-212-3p inhibits glioblastoma cell proliferation by targeting SGK3</article-title><source>J Neurooncol</source><volume>122</volume><fpage>431</fpage><lpage>439</lpage><year>2015</year><pub-id pub-id-type="doi">10.1007/s11060-015-1736-y</pub-id><pub-id pub-id-type="pmid">25720694</pub-id></element-citation></ref>
<ref id="b37-or-38-03-1411"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Killick</surname><given-names>E</given-names></name><name><surname>Morgan</surname><given-names>R</given-names></name><name><surname>Launchbury</surname><given-names>F</given-names></name><name><surname>Bancroft</surname><given-names>E</given-names></name><name><surname>Page</surname><given-names>E</given-names></name><name><surname>Castro</surname><given-names>E</given-names></name><name><surname>Kote-Jarai</surname><given-names>Z</given-names></name><name><surname>Aprikian</surname><given-names>A</given-names></name><name><surname>Blanco</surname><given-names>I</given-names></name><name><surname>Clowes</surname><given-names>V</given-names></name><etal/></person-group><article-title>Role of Engrailed-2 (EN2) as a prostate cancer detection biomarker in genetically high risk men</article-title><source>Sci Rep</source><volume>3</volume><fpage>2059</fpage><year>2013</year><pub-id pub-id-type="doi">10.1038/srep02059</pub-id><pub-id pub-id-type="pmid">23792811</pub-id><pub-id pub-id-type="pmcid">3690389</pub-id></element-citation></ref>
<ref id="b38-or-38-03-1411"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Jo</surname><given-names>H</given-names></name><name><surname>Her</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>HY</given-names></name><name><surname>Ban</surname><given-names>C</given-names></name></person-group><article-title>Ultrasensitive electrochemical detection of engrailed-2 based on homeodomain-specific DNA probe recognition for the diagnosis of prostate cancer</article-title><source>Biosens Bioelectron</source><volume>66</volume><fpage>32</fpage><lpage>38</lpage><year>2015</year><pub-id pub-id-type="doi">10.1016/j.bios.2014.11.003</pub-id><pub-id pub-id-type="pmid">25460878</pub-id></element-citation></ref>
<ref id="b39-or-38-03-1411"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Lai</surname><given-names>C</given-names></name><name><surname>Su</surname><given-names>Z</given-names></name><name><surname>Heng</surname><given-names>B</given-names></name><name><surname>Gao</surname><given-names>S</given-names></name></person-group><article-title>Repression of engrailed 2 inhibits the proliferation and invasion of human bladder cancer <italic>in vitro</italic> and <italic>in vivo</italic></article-title><source>Oncol Rep</source><volume>33</volume><fpage>2319</fpage><lpage>2330</lpage><year>2015</year><pub-id pub-id-type="pmid">25812440</pub-id></element-citation></ref>
<ref id="b40-or-38-03-1411"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abollo-Jim&#x00E9;nez</surname><given-names>F</given-names></name><name><surname>Campos-S&#x00E1;nchez</surname><given-names>E</given-names></name><name><surname>Toboso-Navasa</surname><given-names>A</given-names></name><name><surname>Vicente-Due&#x00F1;as</surname><given-names>C</given-names></name><name><surname>Gonz&#x00E1;lez-Herrero</surname><given-names>I</given-names></name><name><surname>Alonso-Escudero</surname><given-names>E</given-names></name><name><surname>Gonz&#x00E1;lez</surname><given-names>M</given-names></name><name><surname>Segura</surname><given-names>V</given-names></name><name><surname>Blanco</surname><given-names>O</given-names></name><name><surname>Mart&#x00ED;nez-Climent</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Lineage-specific function of Engrailed-2 in the progression of chronic myelogenous leukemia to T-cell blast crisis</article-title><source>Cell Cycle</source><volume>13</volume><fpage>1717</fpage><lpage>1726</lpage><year>2014</year><pub-id pub-id-type="doi">10.4161/cc.28629</pub-id><pub-id pub-id-type="pmid">24675889</pub-id><pub-id pub-id-type="pmcid">4111718</pub-id></element-citation></ref>
</ref-list>
</back>
<floats-group>
<fig id="f1-or-38-03-1411" position="float">
<label>Figure 1.</label>
<caption><p>The expression of miR-212 and EN-2 in clinical specimens and PCa cell lines. (A) The level of miR-212 was downregulated in PCa tissues compared to the adjacent non-tumor tissues. (B) EN-2 in PCa tissues was markedly higher than in the adjacent non-tumor tissues. (C) miR-212 was dramatically decreased in PCa cell linescompared to the prostate epithelial cells (&#x002A;&#x002A;P&#x003C;0.01). (D) EN-2 was significantly increased in PCa cell lines compared to the prostate epithelial cells (&#x002A;&#x002A;P&#x003C;0.01).</p></caption>
<graphic xlink:href="OR-38-03-1411-g00.tif"/>
</fig>
<fig id="f2-or-38-03-1411" position="float">
<label>Figure 2.</label>
<caption><p>The expression level of miR-212 in PCa cell lines transfected with miR-NC, miR-212 mimics. The miR-212 mRNA level was significantly increased in miR-212 mimics when compared with the miR-NC (&#x002A;P&#x003C;0.05).</p></caption>
<graphic xlink:href="OR-38-03-1411-g01.tif"/>
</fig>
<fig id="f3-or-38-03-1411" position="float">
<label>Figure 3.</label>
<caption><p>miR-212 inhibits PCa cell proliferation, invasion and promotes apoptosis. (A) CCK-8 assay showed that miR-212 could inhibit the proliferation of PCa cells, recovery of EN-2 promoted PCa cell proliferation (&#x002A;P&#x003C;0.05 when compared with the miR-NC, <sup>#</sup>P&#x003C;0.05 when compared with the miR-212 mimics). (B and C) TUNEL assay revealed that the apoptosis of PCa cells increased in miR-212 mimics when compared with the miR-NC (&#x002A;P&#x003C;0.05), apoptosis of PCa cells markedly decreased in EN-2 restoration (<sup>#</sup>P&#x003C;0.05 when compared with the miR-212 mimics). (D and E) The invasion ability of PCa cells decreased in upregulation of miR-212 (&#x002A;P&#x003C;0.05 when compared with the miR-NC), recovery of EN-2 promoted the invasion ability (<sup>#</sup>P&#x003C;0.05 when compared with the miR-212 mimics).</p></caption>
<graphic xlink:href="OR-38-03-1411-g02.tif"/>
</fig>
<fig id="f4-or-38-03-1411" position="float">
<label>Figure 4.</label>
<caption><p>miR-212 induces apoptosis of PCa cells. (A) Flow cytometry showed that apoptosis of PCa cells increased after miR-212 upregulation (&#x002A;P&#x003C;0.05 when compared with the miR-NC), and restoration of EN-2 inhibited apoptosis (<sup>#</sup>P&#x003C;0.05 when compared with the miR-212 mimics). (B) The protein expression levels of Bcl-2 and Bax.</p></caption>
<graphic xlink:href="OR-38-03-1411-g03.tif"/>
</fig>
<fig id="f5-or-38-03-1411" position="float">
<label>Figure 5.</label>
<caption><p>miR-212 inhibits PCa cell migration. Wound healing assay demonstrated that upregulation of miR-212 significantly inhibited PCa cell migration (&#x002A;P&#x003C;0.05 when compared with the miR-NC), recovery of EN-2 promoted PCa cell migration (<sup>#</sup>P&#x003C;0.05 when compared with the miR-212 mimics).</p></caption>
<graphic xlink:href="OR-38-03-1411-g04.tif"/>
</fig>
<fig id="f6-or-38-03-1411" position="float">
<label>Figure 6.</label>
<caption><p>EN-2 is a direct target of miR-212. (A) Sequence of miR-212 and the EN-2 3&#x2032;-UTR, which contains a predicted miR-212 biding site. (B) Luciferase assay in PCa cells co-transfected with miR-212 mimics and mimic control containing the EN-2 3&#x2032;-UTR (WT) or a mutant (Mut) (&#x002A;P&#x003C;0.05 when compared with the EN-2 Mut). (C and E) miR-212 transfection suppressed the EN-2 protein and gene levels (&#x002A;P&#x003C;0.05 when compared with the miR-NC).</p></caption>
<graphic xlink:href="OR-38-03-1411-g05.tif"/>
</fig>
<fig id="f7-or-38-03-1411" position="float">
<label>Figure 7.</label>
<caption><p>miR-212 suppresses PCa growth <italic>in vivo</italic>. (A and B) Stable transfection of PCa cells with miR-212 reduced the tumor size (&#x002A;P&#x003C;0.05 when compared with the LV-control).</p></caption>
<graphic xlink:href="OR-38-03-1411-g06.tif"/>
</fig>
<fig id="f8-or-38-03-1411" position="float">
<label>Figure 8.</label>
<caption><p>Overexpression of miR-212 significantly inhibits the level of EN-2. The green indicates decreased, and red increased (A1-A4 indicate miR-NC, B1-B4 indicate miR-212 mimics).</p></caption>
<graphic xlink:href="OR-38-03-1411-g07.tif"/>
</fig>
<table-wrap id="tI-or-38-03-1411" position="float">
<label>Table I.</label>
<caption><p>The relationship between miR-212 expression level and clinicopathological features in our PCa cases.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="bottom">Parameters</th>
<th align="center" valign="bottom">N (case)</th>
<th align="center" valign="bottom">Low (&#x0025;)</th>
<th align="center" valign="bottom">High (&#x0025;)</th>
<th align="center" valign="bottom">P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">Age</td>
<td/>
<td/>
<td/>
<td align="center" valign="top">0.168</td>
</tr>
<tr>
<td align="left" valign="top">&#x00A0;&#x00A0;&#x003C;65</td>
<td align="center" valign="top">13</td>
<td align="center" valign="top">&#x00A0;&#x00A0;7 (53.8)</td>
<td align="center" valign="top">&#x00A0;&#x00A0;6 (46.2)</td>
<td/>
</tr>
<tr>
<td align="left" valign="top">&#x00A0;&#x00A0;&#x2265;65</td>
<td align="center" valign="top">45</td>
<td align="center" valign="top">21 (46.7)</td>
<td align="center" valign="top">24 (53.3)</td>
<td/>
</tr>
<tr>
<td align="left" valign="top">Gleason scores</td>
<td/>
<td/>
<td/>
<td align="center" valign="top">0.005</td>
</tr>
<tr>
<td align="left" valign="top">&#x00A0;&#x00A0;&#x003C;7</td>
<td align="center" valign="top">11</td>
<td align="center" valign="top">&#x00A0;&#x00A0;3 (27.3)</td>
<td align="center" valign="top">&#x00A0;&#x00A0;8 (72.7)</td>
<td/>
</tr>
<tr>
<td align="left" valign="top">&#x00A0;&#x00A0;7</td>
<td align="center" valign="top">17</td>
<td align="center" valign="top">&#x00A0;&#x00A0;8 (47.1)</td>
<td align="center" valign="top">&#x00A0;&#x00A0;9 (52.9)</td>
<td/>
</tr>
<tr>
<td align="left" valign="top">&#x00A0;&#x00A0;&#x003E;7</td>
<td align="center" valign="top">30</td>
<td align="center" valign="top">21 (70.0)</td>
<td align="center" valign="top">&#x00A0;&#x00A0;9 (30.0)</td>
<td/>
</tr>
<tr>
<td align="left" valign="top">Tumor stage</td>
<td/>
<td/>
<td/>
<td align="center" valign="top">0.067</td>
</tr>
<tr>
<td align="left" valign="top">&#x00A0;&#x00A0;&#x2264;T2b</td>
<td align="center" valign="top">43</td>
<td align="center" valign="top">21 (48.8)</td>
<td align="center" valign="top">22 (51.2)</td>
<td/>
</tr>
<tr>
<td align="left" valign="top">&#x00A0;&#x00A0;&#x2265;T3b</td>
<td align="center" valign="top">15</td>
<td align="center" valign="top">&#x00A0;&#x00A0;4 (26.7)</td>
<td align="center" valign="top">11 (73.3)</td>
<td/>
</tr>
<tr>
<td align="left" valign="top">Preoperative PSA level (ng/ml)</td>
<td/>
<td/>
<td/>
<td align="center" valign="top">0.076</td>
</tr>
<tr>
<td align="left" valign="top">&#x00A0;&#x00A0;&#x2264;10</td>
<td align="center" valign="top">11</td>
<td align="center" valign="top">&#x00A0;&#x00A0;8 (72.7)</td>
<td align="center" valign="top">&#x00A0;&#x00A0;3 (27.3)</td>
<td/>
</tr>
<tr>
<td align="left" valign="top">&#x00A0;&#x00A0;&#x003E;10</td>
<td align="center" valign="top">47</td>
<td align="center" valign="top">20 (42.6)</td>
<td align="center" valign="top">27 (57.4)</td>
<td/>
</tr>
<tr>
<td align="left" valign="top">Distant metastasis</td>
<td/>
<td/>
<td/>
<td align="center" valign="top">0.002</td>
</tr>
<tr>
<td align="left" valign="top">&#x00A0;&#x00A0;M0</td>
<td align="center" valign="top">45</td>
<td align="center" valign="top">28 (62.2)</td>
<td align="center" valign="top">17 (37.8)</td>
<td/>
</tr>
<tr>
<td align="left" valign="top">&#x00A0;&#x00A0;M1</td>
<td align="center" valign="top">13</td>
<td align="center" valign="top">&#x00A0;&#x00A0;2 (15.4)</td>
<td align="center" valign="top">11 (84.6)</td>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="tfn1-or-38-03-1411"><p>PCa, prostate cancer, PSA, prostate specific antigen.</p></fn>
</table-wrap-foot>
</table-wrap>
</floats-group>
</article>